BG
BNR

Bellevue Group’s Burning Rock Biotech BNR Stock Holding History

Bellevue Group’s Portfolio BNR Stock Details BNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-43,887
Closed -$4.08M – 174
2022
Q1 		$4.08M Sell
43,887
-5,102
-10% -$443K 0.05% 124
2021
Q4 		$4.67M Hold
48,989
– – 0.05% 128
2021
Q3 		$8.76M Hold
48,989
– – 0.09% 120
2021
Q2 		$14.4M Buy
48,989
+5,696
+13% +$1.69M 0.14% 118
2021
Q1 		$11.7M Buy
43,293
+24,764
+134% +$7.54M 0.12% 118
2020
Q4 		$4.28M Buy
18,529
+3,853
+26% +$1.03M 0.05% 129
2020
Q3 		$3.68M Buy
14,676
+10,176
+226% +$2.41M 0.05% 131
2020
Q2 		$1.22M Buy
+4,500
New +$1.23M 0.02% 142

Other funds holding BNR

Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bellevue Group's BNR Position: Q2 2022 in Review

Bellevue Group sold out of Burning Rock Biotech (BNR) in Q2 2022, closing a stake of 43,887 shares — an estimated $4.08M sold.

Bellevue Group first reported a position in BNR in Q2 2020 and held it in 8 quarters. The position peaked at $14.4M in Q2 2021. 50 funds tracked by Wall St. Rank hold BNR as of Q2 2022.

  • Bellevue Group reported no remaining Burning Rock Biotech position as of Q2 2022 after selling out during the quarter.
  • Bellevue Group sold 43,887 Burning Rock Biotech shares in Q2 2022, an estimated $4.08M.
  • Bellevue Group first reported a position in Burning Rock Biotech in Q2 2020 and held it in 8 quarters.
  • Bellevue Group's Burning Rock Biotech position peaked at $14.4M in Q2 2021.
  • 50 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q2 2022.

Based on Bellevue Group's 13F filing for Q2 2022, filed 11 Aug 2022.